The Samuel Waxman Cancer Research Foundation is pleased to announce The Gladstein Family Bladder Cancer Research Program. This is a Request for Applications (RFA) for 2 (two) new two-year awards of $100,000/year. We focus funding on the interplay of aging and cancer and research that will address aspects of aberrant gene expression, differentiation, or epigenetic therapies that relate to bladder cancer. Directors of major aging and cancer research programs are invited to submit one application per institution.

Potential themes related to aging and inflammation in bladder cancer include:

- Aging-associated changes in stem cell function related to bladder cancer
- Mechanisms of age-associated clonal evolution in somatic tissues
- Chromatin/epigenetic mechanisms in aging and bladder cancer
- Mutation and/or de-repression of non-coding genome in aging and bladder cancer
- Aging-associated DNA damage response pathways and genomic instability in bladder cancer
- Changes in metabolism related to bladder cancer
- Decline in tissue maintenance as a potential link to bladder cancer incidence
- Contributions of the microenvironment and immune function in bladder cancer formation
- Inter-organ system communication in aging and bladder cancer
- Human model systems of aging-associated bladder cancer
- Novel mouse models to study the role of aging in bladder cancer
- Novel intervention to prevent inflammation related to bladder cancer

Based on its long-standing interest in differentiation therapy for cancer, the SWCRF will continue to solicit applications related to:

- Transcription-based approaches to bladder cancer
- Novel therapies/pathways to overcome defective differentiation of cancer cells
- Targeting aberrant signaling pathways characteristic of the malignant phenotype
- Selective apoptotic agents and pathways in bladder cancer

Recipients of the SWCRF cancer research awards are encouraged to develop collaborations with other SWCRF investigators to continue scientific interactions beyond the term of their grant and form a society of investigators committed to:

**Collaboration:**

- Formulation of research plans to augment other SWCRF research programs
- Sharing of research materials, reagents, and/or core resources
- Joint publications
- Development of NIH program project grants (P01s) and/or collaborative R01s
Communication:
Interactions at the annual SWCRF Scientific Review Meeting
Subgroup meetings at other meetings such as ASH and AACR

**2020 RFA Guidelines**

Each center may nominate one Principal Investigator to apply for a two-year grant for up to $200,000 ($100,000 per year, which may include up to 10% for overhead).

**Timeline:**

<table>
<thead>
<tr>
<th>Activity</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submit structured letter of intent (LOI) using the template below</td>
<td>March 15, 2020</td>
</tr>
<tr>
<td>Invitations for Full Application</td>
<td>April 15, 2020</td>
</tr>
<tr>
<td>Full application</td>
<td>June 1, 2020</td>
</tr>
<tr>
<td>Funding decision</td>
<td>July 1, 2020</td>
</tr>
</tbody>
</table>

Funding decisions will be made by peer review, SWCRF Scientific Advisory Board, SWCRF Founder and CEO, Chief Scientific Officer and Chief Mission Officer. Reporting results and the budget process will be discussed at the time of announcement of the awards.

Submit all inquiries and responses to Mr. Jesse Dean jdean@waxmancancer.org and Ms. Lyris Skinner lyris.skinner@mssm.edu.

**About the SWCRF**

The Samuel Waxman Cancer Research Foundation (SWCRF), founded in 1975, is a non-profit organization dedicated to conducting basic, translational, and clinical research with the goal of developing effective targeted treatments for cancer. SWCRF funds research in leading institutions in the United States, Canada, China, and Israel; fosters collaborations; trains scientists; and organizes international conferences to develop novel approaches to prevent and treat cancer. SWCRF develops research programs in the form of an “Institution Without Walls™” that spans institutions and disciplines and seeks to identify investigators who are best able to attack specific problems related to cancer. To date, the SWCRF has awarded more than $100 million to more than 200 investigators.

Samuel Waxman, MD  
Founder & CEO  
SWCRF

Johnathan D. Licht, MD  
Chief Scientific Officer  
SWCRF

Alan Rosmarin, MD  
Chief Mission Officer  
SWCRF

William T. Sullivan  
Executive Director  
SWCRF
Letter of Intent (1 page)

Samuel Waxman Cancer Research Foundation
2020 Cancer Research Awards

Title:

PI name, Institution:

Background:

Premise:

Key preliminary data:

Hypothesis:

Specific Aims:

Novelty:

Impact: